“My talk [highlights] unmet research needs that need to be addressed to further improve the adjuvant treatment landscape for our patients,” said Pavlos Msaouel, MD, PhD.
In this video, Pavlos Msaouel, MD, PhD, discusses the key points of his presentation, “The future of adjuvant therapy for high-risk non-metastatic RCC,” presented during the 2021 Society of Urologic Oncology Annual Meeting. Msaouel is an assistant professor in the department of genitourinary medical oncology of the division of cancer medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.